Sudarshan Pharma

Why is Sudarshan Pharma Industries Ltd falling/rising?

As of 14-Jul, Sudarshan Pharma Industries Ltd's stock price is at Rs. 41.96, having increased by 0.6%. The stock has shown strong performance with a 52.30% year-to-date rise, reaching a new 52-week high, supported by robust financial results and consistent returns.

As of 14-Jul, Sudarshan Pharma Industries Ltd's stock price is rising, currently at Rs. 41.96, reflecting an increase of 0.25 (0.6%). The stock has shown a strong performance over various time frames, with a notable 4.20% increase over the past week and a remarkable 17.54% rise over the past month. Year-to-date, the stock has surged by 52.30%, significantly outperforming the Sensex, which has declined by 9.58% during the same period.<BR><BR>Today, the stock reached a new 52-week high of Rs. 42 and has been gaining for the last two days, accumulating a total return of 5% in this short span. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. Despite a recent decline in investor participation, with delivery volume dropping by 25.79% compared to the 5-day average, the stock remains liquid enough for trading.<BR><BR>The positive financial performance of Sudarshan Pharma also supports its rising stock price. The company reported its highest quarterly net sales at Rs. 220.92 crore and a significant increase in operating profit, with a 47.89% annual growth rate. The stock has generated a return of 44.69% over the past year, while profits have increased by 36%, contributing to an attractive valuation with a PEG ratio of 1.3.<BR><BR>Overall, the combination of strong financial results, consistent returns over the past three years, and the stock's performance relative to benchmarks has contributed to the upward movement in Sudarshan Pharma Industries Ltd's stock price.

Which are the latest news on Sudarshan Pharma?

Should I buy, sell or hold Sudarshan Pharma Industries Ltd?

What does Sudarshan Pharma do?

Sudarshan Pharma Industries Ltd is a micro-cap company in the specialty chemicals industry, with net sales of 221 Cr and a net profit of 11 Cr reported for March 2026. It was incorporated in 2008 and has a market cap of INR 842 Cr.

Overview:<BR>Sudarshan Pharma Industries Ltd operates in the specialty chemicals industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was initially incorporated in 2008 as "Sudarshan Specialty Chemsolve Private Limited" and later changed its name to "Sudarshan Pharma Industries Private Limited" in December 2016. The most recent quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 221 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 11 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 842 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 36.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.85 <BR>Return on Equity: 14.39% <BR>Price to Book: 5.52 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Sudarshan Pharma?

As of 10th June, Sudarshan Pharma Industries Ltd has a market capitalization of 842.00 Cr, with net sales of 703.06 Cr and a net profit of 23.31 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Sudarshan Pharma Industries Ltd has a market capitalization of 842.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 703.06 Cr, while the sum of Net Profit for the same period is 23.31 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 131.48 Cr, and Total Assets amount to 402.41 Cr.

Who are in the management team of Sudarshan Pharma?

The management team of Sudarshan Pharma includes Hemal V Mehta (Managing Director), Sachin V Mehta (Joint Managing Director & CFO), Ujwala Vilas Salvi, Subhash Goverdhandasji Bissa (Directors), and Rushabh Prashant Patil (Additional Director).

The management team of Sudarshan Pharma includes the following individuals:<BR><BR>1. Hemal V Mehta - Managing Director<BR>2. Sachin V Mehta - Joint Managing Director & CFO<BR>3. Ujwala Vilas Salvi - Director<BR>4. Subhash Goverdhandasji Bissa - Director<BR>5. Rushabh Prashant Patil - Additional Director<BR><BR>If you need more information about their roles or the company's operations, feel free to ask!

Who are the peers of the Sudarshan Pharma?

Sudarshan Pharma's peers include Oriental Aromatics, Sunshield Chemicals, Jyoti Resins, Indo Amines, Gem Aromatics, Valiant Organics, Fairchem Organic, Chemcon Specialties, Amal, and Sacheerome. Sudarshan Pharma has below-average growth and capital structure ratings, with a 1-year return of 12.11%, better than Valiant Organics but lower than Sunshield Chemicals' 55.62%.

Peers: The peers of Sudarshan Pharma are Oriental Aromat., Sunshield Chem., Jyoti Resins, Indo Amines, Gem Aromatics, Valiant Organics, Fairchem Organic, Chemcon Special., Amal, and Sacheerome.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jyoti Resins and Sacheerome, while Average management risk is found at Oriental Aromat., Sunshield Chem., Indo Amines, Gem Aromatics, Valiant Organics, Fairchem Organic, Amal, and Sudarshan Pharma. Growth is Excellent at Jyoti Resins and Sacheerome, while Average growth is noted at Oriental Aromat., Sunshield Chem., Indo Amines, Valiant Organics, Fairchem Organic, and Amal, and Below Average growth is seen at Gem Aromatics and Sudarshan Pharma. Capital Structure ratings show Excellent at Chemcon Special., Good at Gem Aromatics and Fairchem Organic, Below Average at Sudarshan Pharma, Indo Amines, and Valiant Organics, and Average at the rest.<BR><BR>Return Snapshot: Sunshield Chem. has the highest 1-year return at 55.62%, while Valiant Organics has the lowest at -44.11%. Sudarshan Pharma's 1-year return of 12.11% is better than Valiant Organics but lower than Sunshield Chem. Additionally, the six-month return is negative for Valiant Organics, Fairchem Organic, and Amal.

When is the next results date for Sudarshan Pharma Industries Ltd?

The next results date for Sudarshan Pharma Industries Ltd is April 30, 2026.

The next results date for Sudarshan Pharma Industries Ltd is scheduled for April 30, 2026.

Are Sudarshan Pharma Industries Ltd latest results good or bad?

Sudarshan Pharma Industries Ltd's latest results show strong revenue growth of 45.26% year-on-year and a net profit increase of 51.39%, but declining operating and profit margins raise concerns about profitability and financial stability.

Sudarshan Pharma Industries Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹4.36 crore for Q3 FY26, which is a significant increase of 51.39% year-on-year. Revenue also saw a robust growth of 45.26% year-on-year, reaching ₹168.01 crore. This indicates strong demand for their specialty chemical products and impressive revenue momentum.<BR><BR>However, there are notable concerns regarding profitability margins. The operating margin has decreased to 6.47%, down from 10.14% in the same quarter last year, indicating pressure on operational efficiency. Additionally, the profit after tax (PAT) margin has compressed to 2.47%, significantly lower than previous levels. The company is facing rising interest costs, which surged to ₹6.28 crore in Q3 FY26, consuming a substantial portion of operating profits.<BR><BR>Overall, while Sudarshan Pharma shows strong revenue growth, the decline in margins and increasing debt levels raise concerns about its profitability and financial stability. The company is navigating a challenging environment, balancing growth with the need for improved operational efficiency.

Is Sudarshan Pharma technically bullish or bearish?

As of December 4, 2025, Sudarshan Pharma's technical trend is mildly bearish, with indicators like the MACD and moving averages supporting this outlook, despite some mild bullishness from the KST and a neutral RSI.

As of 4 December 2025, the technical trend for Sudarshan Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD indicating bearish momentum and the moving averages also reflecting a mildly bearish outlook. The Bollinger Bands confirm this sentiment on both weekly and monthly time frames. Although the KST shows mild bullishness weekly, it is not strong enough to counter the overall bearish indicators. The RSI shows no signal, indicating a lack of momentum in either direction. Overall, the technical indicators suggest a cautious approach given the prevailing mildly bearish conditions.

Is Sudarshan Pharma overvalued or undervalued?

As of November 10, 2025, Sudarshan Pharma is considered very expensive and overvalued with a PE ratio of 42.23, significantly underperforming the market with a 36.43% decline year-to-date, compared to its peers like Sun Pharma and Divi's Lab.

As of 10 November 2025, Sudarshan Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 42.23, an EV to EBITDA of 22.69, and a PEG ratio of 1.01. These figures suggest that the stock is trading at a premium compared to its earnings and growth potential.<BR><BR>In comparison to its peers, Sudarshan Pharma's valuation stands out, with Sun Pharma at a PE of 35.15 and Divi's Lab at a staggering 71.55, both categorized as very expensive. Other competitors like Cipla and Dr. Reddy's Labs are considered attractive, with PE ratios of 22.45 and 17.33, respectively. The stark contrast in valuation metrics highlights Sudarshan Pharma's overvaluation. Additionally, the company's stock has underperformed significantly year-to-date, down 36.43%, compared to a 6.91% gain in the Sensex, reinforcing the notion that it is overvalued in the current market environment.

How has been the historical performance of Sudarshan Pharma?

Sudarshan Pharma has shown consistent growth from March 2022 to March 2025, with net sales increasing from 357.09 Cr to 505.05 Cr, and profit after tax rising from 5.25 Cr to 15.95 Cr, alongside significant improvements in operating cash flow and total assets. The company's financial performance reflects a strong upward trend in sales, profitability, and asset growth.

Answer:<BR>The historical performance of Sudarshan Pharma shows a consistent growth trajectory in net sales and profits over the past four years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Sudarshan Pharma's net sales increased from 357.09 Cr in March 2022 to 505.05 Cr in March 2025, reflecting a robust growth trend. Total operating income followed a similar pattern, rising from 357.09 Cr in March 2022 to 505.05 Cr in March 2025. The company's operating profit (PBDIT) also saw significant growth, climbing from 11.38 Cr in March 2022 to 42.44 Cr in March 2025, while the profit before tax rose from 7.14 Cr to 21.63 Cr in the same period. Consequently, profit after tax increased from 5.25 Cr in March 2022 to 15.95 Cr in March 2025, indicating improved profitability. The company's total assets grew substantially from 137.52 Cr in March 2022 to 402.41 Cr in March 2025, driven by increases in both current and non-current assets. Total liabilities also rose, from 137.52 Cr to 402.41 Cr, primarily due to higher short-term borrowings, which increased from 25.65 Cr to 160.27 Cr. Cash flow from operating activities improved significantly, moving from a negative 3 Cr in March 2022 to a positive 35 Cr in March 2025, highlighting enhanced operational efficiency. Overall, Sudarshan Pharma's financial performance demonstrates a strong upward trend in sales, profitability, and asset growth over the analyzed period.

Who are the top shareholders of the Sudarshan Pharma?

The top shareholders of Sudarshan Pharma include promoter Sachin Vasantrai Mehta with 27.51%, 11 Foreign Institutional Investors holding 18.45%, and public shareholder Multitude Growth Funds Limited at 5.52%. Individual investors own 18.18% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sudarshan Pharma include the promoters, with Sachin Vasantrai Mehta holding the highest stake at 27.51%. Additionally, 11 Foreign Institutional Investors (FIIs) collectively hold 18.45% of the shares. The highest public shareholder is Multitude Growth Funds Limited, which owns 5.52%. Individual investors also have a significant presence, holding 18.18% of the company's shares. There are no pledged promoter holdings, and no mutual funds are currently invested in the company.

Has Sudarshan Pharma declared dividend?

Sudarshan Pharma Industries Ltd has declared a 3% dividend, amounting to 0.3 per share, with an ex-date of August 25, 2023. Despite this, the dividend yield is 0%, and the total returns over the last six months are -26.55%, while the past year shows a significant gain of 367.73%.

Sudarshan Pharma Industries Ltd has declared a 3% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 3%<BR>- Amount per share: 0.3<BR>- Ex-date: 25 Aug 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>Over the last 6 months, the price return was -26.55%, with a dividend return of 0%, resulting in a total return of -26.55%.<BR><BR>In the past year, the price return was 367.73%, with a dividend return of 0%, leading to a total return of 367.73%.<BR><BR>Over 2 years, the price return was 360.75%, with a dividend return of 0%, resulting in a total return of 360.75%.<BR><BR>For the 3-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>In the last 4 years, the price return was 0%, with a dividend return of 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, there was no price return, no dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Sudarshan Pharma has declared a dividend, the dividend yield remains at 0%. The total returns show significant gains over the past year and two years, but recent performance over the last six months has been negative.